Non-Hodgkin lymphoma (NHL) is the fifth most prevalent cancer in Canada and is responsible for 3-4% of all cancer-related deaths. Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is the most common NHL subtype, and accounts for 90% of aggressive cases. DLBCL originates from activated and germinal B-cells, with those originating from activated B-cells having a poorer prognosis. MicroRNA (MIR142), which plays a crucial role in tumour suppression and is mutated in approximately 20% of DLBCL cases. Understanding the specific targets regualted by MIR142 could lead to new therapeutic strategies for DLBCL patients unresponsive to current treatments. 

Identifying MIR142 targets driving tumourigenesis could lead to new therapeutic strategies for DLBCL patients unresponsive to current treatments. By focusing on drug-based suppression of dysregulated MIR142 targets, there is potential to prevent tumour progression and improve patient outcomes.